Actively Recruiting
Phase I Study of Thermotherapy Added to Standard Chemoradiotherapy or Radiotherapy for Locally Advanced Head and Neck Cancer
Led by Erasmus Medical Center · Updated on 2026-09-02
30
Participants Needed
1
Research Sites
165 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and optimal dose of mild hyperthermia thermotherapy combined with standard treatment in patients with locally advanced head and neck squamous cell carcinoma LAHNSCC. Despite chemoradiotherapy, tumor recurrence is common, so this study aims to explore if adding thermotherapy, which raises tumor temperature to 39-45C, can improve treatment outcomes. This is a phase I, single-center trial designed to find a recommended phase II dose and assess safety in two patient groups. The study includes two groups one receiving thermotherapy with chemoradiotherapy using a dose-escalation method guided by a Bayesian design to identify dose-limiting toxicities, and another receiving thermotherapy with radiotherapy alone to assess tolerability. Thermotherapy is given weekly using the HyperCollar3D device, targeting tumors and involved lymph nodes with precise heating. Optional invasive temperature measurements may be done in some participants. Participants will be monitored from before treatment through up to six months after completion, with assessments of safety, side effects such as mild trismus, and ability to complete treatments. Researchers will also explore tumor control and survival outcomes. The total participation duration includes treatment weeks plus follow-up, helping to identify a safe and feasible thermotherapy dose to potentially improve care for LAHNSCC patients.
CONDITIONS
Brief Title
Thermotherapy for Head and Neck Cancer Patients
Research Team
M
Michiel Kroesen, MD, Dr.
T
Tessa L. Coenraad, MSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here